Factors associated with mortality of patients with myxoedema coma: Prospective study in 11 cases treated in a single institution

Journal of Endocrinology

Volumn 180, Issue 2, 2004, Pages 347-350

  Rodriguez I ^a   Fluiters, E ^a   Perez Mendez L F ^a   Luna, R ^a   Paramo C ^a   García Mayor, Ricardo V ^a,b  

^a University Hospital of Vigo   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; HYDROCORTISONE ACETATE; LEVOTHYROXINE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FREE THYROXINE INDEX; GLASGOW COMA SCALE; HUMAN; MALE; MORTALITY; MYXEDEMA; OUTCOMES RESEARCH; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; AGED; APACHE; COMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLASGOW COMA SCALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYXEDEMA; PROSPECTIVE STUDIES; SURVIVAL RATE; THYROXINE;

EID: 1542301066     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1800347     Document Type: Article

References (13)

1. Galofré JC & García-Mayor RV 1997 Densidad de incidencia del coma mixedematoso. Endocrinología 44 103-104.
2. Holvey DN, Goodner CJ, Nicoloff JT & Dowling J 1964 Treatment of myxoedema coma with intravenous thyroxine. Archives of Internal Medicine 113 139-146.
3. Hylander B & Rosenquist U 1985 Treatment of myxoedema coma factors associated with fatal outcome. Acta Endocrinologica 108 65-71.
4. Jordan RM 1995 Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Medical Clinics of North America 79 185-194.
5. Khaleeli AA 1978 Myxxoedema coma. A report of five successfully treated cases. Postgraduate Medical Journal 54 825-829.
6. Knaus WA, Draper EA, Wagner DP & Zimmerman JE 1985 APACHE II: a severity of disease classification system. Critical Care Medicine 13 818-829.
7. Olalla Gallo MA, Hernansanz de la Calle S, Hernández Bezos S, Fadrique Toledano R, Majo Fierro T & Gandia Martí nez F 1999 Evaluación del APACHE II como sistema de estratificación de gravedad en unidades de observación de urgencias. Emergencias 11 26-33.
8. Pereira VG, Haron ES, Lima-Neto G & Medeiros-Neto GA 1982 Management of myxedema coma: report of three successfully treated cases with nasogastric or intravenous administration of triiodothyronine. Journal of Endocrinological Investigation 5 331-334.
9. Reinhardt W & Mann K 1997 Hä ufigkeit, klinisches Bild und Behandlung des hypothyreoten Komas. Ergebnis einer Umfrage. Medizinische Klinik 92 521-524.
10. Ridgway EC, McCammon JA, Benotti J & Maloof F 1972 Acute metabolic response in myxedema to large doses of intravenous L-thyroxine. Annals of Internal Medicine 77 549-555.
11. Tsitouras PD 1995 Myxedema coma. Clinical Geriatric Medicine 11 251-258.
12. Wilson JT, Pettigrew LE & Teasdale GM 1998 Structured interviews for the Glasgow Outcome scale and the extended Glasgow Outcome scale: guidelines for their use. Journal of Neurotrauma 8 573-585.
13. Yamamoto T, Kukurama J & Fujiyoshi A 1999 Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 9 1167-1172.